Effectiveness of electronic cigarettes compared with combination nicotine replacement therapy for smoking cessation in patients with chronic obstructive pulmonary disease and effect on lung health (ECAL Trial).

niversity of Birmingham0 个研究点目标入组 1,250 人开始时间: 2023年10月4日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•1. COPD diagnosis previously confirmed by post-bronchodilator spirometry (FEV1/FVC <0.7), any GOLD stage
•2. Current smoker (=5 cigarettes per day)
•3. Motivated to stop smoking
•4. Aged 35 or over

•1. Unable to perform spirometry to a satisfactory standard (e.g. due to dementia, lack of teeth, lack of coordination or not having a good oral seal)
•2. Deemed as unsuitable to participate in the trial (e.g. terminal illness, unable to give informed consent)
•3. Unable to participate in behaviour support calls
•4. Severe angina or unstable cardiovascular disease
•5. History of end stage kidney disease
•6. History of cirrhosis of the liver
•7. Currently taking NRT, bupropion, varenicline or ECs to stop or reduce smoking
•8. Currently taking part in another trial of smoking cessation or COPD treatment/management
•9. COPD exacerbation or inpatient hospital stay within the last 8 weeks (invite back and re-assess after 8 weeks)
•10. Contraindications to spirometry within the last 12 weeks – tuberculosis infection, cardiac infarction, retinal detachment or surgery on the chest, abdomen, brain, ears or eyes (invite back and re-assess after 12 weeks)

发起方